Phase IIa clinical

Related by string. phase IIa clinical * phase . phases . Phases . PHASE : Phase III clinical trials . Phase III trials . pivotal Phase III . ongoing Phase 1b / IIA . IIAS : Phase IIa clinical trials . IIa clinical trial . Phase IIa . Phase IIa trial / clinicals . CLINICAL . Clinicals : Phase III clinical . Phase 2b clinical . placebo controlled clinical trials * Phase IIa Clinical Trial *

Related by context. All words. (Click for frequent words.) 85 Phase 2a clinical 82 phase IIa clinical 80 Phase Ib clinical 80 Phase IIa 79 Phase III clinical 79 Phase 2a 79 Phase 2b clinical 79 Phase IIa trial 79 Phase IIb clinical 78 Phase 1b clinical 78 phase IIa 77 Phase Ib 77 Phase 2b study 77 phase IIb 77 phase IIb clinical 76 pivotal Phase III 76 Phase IIIb clinical 76 Phase 2a trial 76 Phase 2b trial 75 phase 2a 75 Phase IIb 75 Phase III 75 Phase Ib study 75 Phase IIb trial 75 Phase Ia 74 confirmatory Phase III 74 Phase 1b 73 Phase 1a clinical 73 Phase 1a 73 Phase 1b trial 73 Phase 2b 72 phase Ib clinical 71 dose escalation trial 71 Phase Ib II 71 Phase II 71 Phase III clinical trials 71 pharmacokinetic PK study 70 placebo controlled Phase 70 Phase IIb trials 70 dose escalation Phase 70 pharmacokinetic PK 70 phase Ib 70 Phase III pivotal 70 dose escalation clinical 70 phase IIb trial 69 placebo controlled clinical 69 randomized controlled Phase 69 Phase #b/#a 69 multiple ascending dose 69 clinical trial 69 pivotal Phase 69 Phase 2b clinical trials 69 Phase III placebo controlled 69 BRIM3 69 phase IIb study 69 JAK inhibitor 69 INCB# [001] 69 multicenter Phase 69 KRN# 69 Phase #/#a 69 alvespimycin 68 pharmacokinetics PK 68 Phase IIB 68 dose escalation study 68 Phase IIIb 68 multicenter Phase II 68 randomized Phase IIb 68 Phase Ib IIa 68 Phase IIa clinical trials 68 APEX PD 68 Phase IIa trials 68 NP2 Enkephalin 68 cannabinor 67 registrational 67 FOLOTYN ® 67 Phase III trials 67 bicifadine 67 Phase III confirmatory 67 davunetide intranasal AL 67 BRIM2 67 CEQ# 67 Phase IIb III 67 multicenter randomized Phase 67 Phase #b/#a clinical 67 randomized Phase III 67 Phase Ib clinical trials 67 investigational compound 67 NGX# 66 Fx #A 66 tanespimycin 66 MEND CABG 66 oral ridaforolimus 66 confirmatory Phase 3 66 fostamatinib 66 Cloretazine ® 66 velafermin 66 ADVANCE PD 66 oral prodrug 66 lorvotuzumab mertansine 66 Phase III randomized controlled 66 single ascending dose 66 Annamycin 66 randomized Phase 66 PRX # 66 Archexin 66 Azedra 66 MAP# 66 rALLy clinical trial 66 ATL# [001] 66 dirucotide 66 Corlux 66 CR# vcMMAE 66 elotuzumab 66 investigational drug 66 IMA# 66 IIa trial 65 glufosfamide 65 RSD# oral 65 Plicera 65 ELND# 65 PEG PAL 65 Phenoptin 65 lomitapide 65 Amrubicin 65 ISIS # 65 Phase 2a clinical trials 65 multicenter clinical 65 ocrelizumab 65 SUCCEED trial 65 ganetespib 65 fosbretabulin 65 preclinical 65 IMGN# 65 Alzhemed TM 65 Pimavanserin 65 Phase IIb clinical trials 65 R#/MEM # 65 Zenvia Phase III 65 ELACYT 65 ongoing Phase 1b 65 Phase #b/#a trial 65 Mipomersen 65 placebo controlled 65 diabetic neuropathic pain 65 relapsing remitting multiple sclerosis 65 ZYBRESTAT 65 neurogenic orthostatic hypotension 65 aclidinium bromide 65 Dacogen injection 65 placebo controlled Phase III 65 ORMD 65 PDE4 inhibitor 65 QLT# 65 multicentre randomized 65 viral kinetic 65 TACI Ig 65 elacytarabine 65 Laquinimod 65 randomized multicenter 65 GALNS 65 phase IIIb 65 phase IIb III 65 Sym# 64 ILLUMINATE 64 randomized Phase 2b 64 Phase 2b randomized 64 OvaRex ® MAb 64 PDX pralatrexate 64 multicenter randomized placebo controlled 64 CB2 selective receptor agonist 64 teduglutide 64 histone deacetylase HDAC inhibitor 64 pharmacokinetic 64 preclinical studies 64 IIa clinical trial 64 preclinical efficacy 64 CRLX# 64 pivotal bioequivalence 64 subcutaneously administered 64 subcutaneous formulation 64 Phase 2b monotherapy 64 Traficet EN 64 huN# DM1 64 Pivotal Phase III 64 varespladib 64 Omacetaxine 64 relapsing multiple sclerosis 64 Randomized Phase 64 EDEMA3 64 PHX# 64 blinded randomized placebo controlled 64 GLPG# 64 safety tolerability 64 vascular disrupting agent 64 Androxal TM 64 brivaracetam 64 GAMMAGARD 64 Zenvia ™ 64 registrational trial 64 MERLIN TIMI 64 virus HCV protease inhibitor 64 teriflunomide 64 Phase 1b dose escalation 64 refractory gout 64 Bezielle 64 Microplasmin 64 Phase III psoriasis 64 ENDEAVOR IV 64 TMC# C# 64 forodesine 64 huC# DM4 64 TBC# 64 INCB# [002] 64 Cloretazine R VNP#M 64 Safinamide 64 lintuzumab 64 dyskinesia PD LID 63 ruxolitinib 63 axitinib 63 mertansine 63 PD LID 63 double blinded placebo 63 PFO migraine 63 GLP toxicology studies 63 clinical trials 63 Triolex 63 double blind placebo 63 OncoVEX GM CSF 63 OHR/AVR# 63 midstage trials 63 PS# DARA 63 humanized anti 63 IIa clinical 63 relapsed multiple myeloma 63 relapsed refractory multiple myeloma 63 omacetaxine mepesuccinate 63 Aurexis 63 Proxinium TM 63 LymphoStat B TM 63 orally bioavailable 63 fidaxomicin Phase 3 63 denufosol 63 Virulizin ® 63 vidofludimus 63 evaluating tivozanib 63 ALN TTR# 63 AEZS 63 investigational pan BCR 63 Phase 2b kidney transplant 63 Plecanatide 63 II Clinical Trial 63 NO# [002] 63 Phase IIb Trial 63 Azixa 63 ZYBRESTAT fosbretabulin 63 HuMax CD4 63 unblinding 63 Lu AA# 63 Daclizumab 63 AP# [003] 63 CBLC# 63 ABSORB trial 63 AZILECT R 63 ADAGIO study 63 Alocrest 63 RhuDex ® 63 initiate Phase 1b 63 investigational humanized monoclonal antibody 63 Initiated Phase 63 tezampanel 63 methylnaltrexone 63 TASKi2 63 Memryte 63 trodusquemine 63 SUVN 63 dacetuzumab 63 Zerenex 63 multicenter Phase III 63 IND submission 63 Bicifadine 63 LymphoStat B 63 Phase III Pivotal 63 Reolysin 63 HGS ETR1 63 Phase 63 PRT# 63 EOquin 63 DermaVir Patch 63 initiate Phase IIb 62 PXD# 62 Troxatyl 62 Phase #/#a clinical 62 LUX Lung 62 Atiprimod 62 investigational hepatitis C 62 NASDAQ CXSP announced 62 HCV SPRINT 62 LCP Tacro 62 dosing cohorts 62 clinical pharmacology studies 62 HspE7 62 obatoclax 62 multicenter randomized controlled 62 PRTX 62 ProSavin 62 Initiate Phase 62 JAK2 inhibitor 62 Tarvacin TM 62 NASDAQ ARRY 62 SPIRIT FIRST 62 PEG SN# 62 picoplatin 62 Allovectin 7 62 dimebon 62 VNP#M 62 Ambrisentan 62 multicenter placebo controlled 62 multicenter phase 62 Aryplase 62 EOquin TM 62 tolerability 62 Aflibercept 62 laquinimod 62 Phase III HEAT 62 dose cohorts 62 belinostat 62 radiation sensitizer 62 Enzastaurin 62 deforolimus 62 Ocrelizumab 62 rindopepimut 62 cell lymphoma CTCL 62 enzastaurin 62 YONDELIS 62 AeroLEF TM 62 bardoxolone 62 Quinamed 62 alemtuzumab Campath 62 TG MV 62 orally inhaled migraine 62 lumiliximab 62 MAGE A3 ASCI 62 pharmacodynamic PD 62 TELINTRA 62 Medidur TM FA 62 torezolid phosphate 62 prucalopride 62 PRIMO CABG 62 phase III ACCLAIM 62 satraplatin Phase 62 Phase IIb kidney transplant 62 CUSTOM III 62 oral deforolimus 62 Phase III multicenter 62 Nasdaq MAPP 62 pomalidomide 62 PS# [001] 62 initiate Phase IIa 62 dexanabinol 62 Cannabinor 62 Pirfenidone 62 HCV RESPOND 2 62 romidepsin 62 TMC# [002] 62 double blinded randomized 62 Elagolix 62 DDP# 62 L Annamycin 62 Ophena TM 62 pertuzumab 62 MEND CABG II 62 IMPACT IMmunotherapy 62 eculizumab 62 Phase III randomized 62 interferon beta 1b 62 Oglemilast 62 R#/MEM 62 Fodosine 62 SYMMETRY trial 62 Tarceva TM 62 mipomersen 62 COMFORT II 62 ofatumumab 62 PREOS 62 tiapamil 62 initiated Phase Ib 62 cathepsin K inhibitor 62 PSN# [002] 62 RDEA# 62 ABSORB clinical 62 BAY #-# 62 CYT# 62 NVA# 62 zanolimumab 62 Nasdaq VRTX 62 tramiprosate Alzhemed TM 62 riociguat 62 Phase 1b clinical trials 62 IL# PE#QQR 62 Pivotal Phase 62 EGS# 62 non nucleoside inhibitor 62 rilonacept 62 MIST II 62 reslizumab 62 compound INCB# 62 XL# XL# XL# 62 ILUVIEN ® 62 trastuzumab emtansine T DM1 62 recurrent glioblastoma multiforme 61 pharmacokinetic studies 61 randomized placebo controlled 61 trial evaluating PRX# 61 tasimelteon 61 Tanespimycin 61 opioid induced bowel dysfunction 61 Phase III ALLEGRO 61 label multicenter 61 Spiegelmer ® 61 GSK# [002] 61 HQK 61 prospective multicenter randomized 61 #th Annual Interscience 61 VA# [002] 61 Ceflatonin R 61 Factor VIIa 61 treatment naive genotype 61 Phase IIA 61 Sprycel dasatinib 61 RG# [001] 61 pseudobulbar affect PBA 61 initiate Phase Ib 61 KNS # 61 initiate Phase 2b 61 ProLindac 61 alvimopan 61 TELCYTA 61 AQ4N 61 REG2 61 selective androgen receptor modulator 61 Phase III Clinical Trials 61 orBec 61 tramiprosate 61 midstage clinical 61 liposomal formulation 61 aflibercept 61 docetaxel Taxotere R 61 Guanilib 61 Serdaxin 61 LEVADEX ™ 61 ataluren 61 APEX AMI trial 61 metaglidasen 61 vosaroxin 61 XL# SAR# 61 eniluracil 61 Urocidin 61 lintuzumab SGN 61 trastuzumab DM1 T DM1 61 randomized multicenter Phase III 61 Cethrin R 61 rALLy trial 61 Phase III VISTA 61 LEVADEX 61 multicenter prospective 61 OncoGel 61 ANAVEX #-# [003] 61 HGS# 61 Tyrima 61 OvaRex R 61 Diabetic Macular Edema DME 61 HuMax CD# 61 Dextofisopam 61 PRECiSE 61 Fibrillex TM 61 multicenter randomized double 61 LAF# 61 pharmacodynamic profile 61 Prostate AdenoCarcinoma Treatment 61 Onalta 61 nucleotide analog 61 HuMax EGFr 61 safety tolerability pharmacokinetic 61 oral formulation 61 Onalta ™ 61 TASKi3 61 PROSTVAC TM 61 anticancer compound 61 blinatumomab 61 prospective multicenter 61 ANCHOR trial 61 rNAPc2 61 Multiple Ascending Dose 61 CRx 61 ToGA 61 atacicept 61 novel oral anticoagulant 61 PF # [001] 61 dose cohort 61 DEB# 61 ThermoDox R 61 ARRY 61 cystinosis patients 61 desvenlafaxine succinate 61 BNC# 61 AEG# 61 Unit Dose Budesonide 61 CCR5 antagonist 61 Combination REOLYSIN R 61 MEK inhibitor 61 PF # [002] 61 Glybera R 61 CDP# 61 GRN# 61 label multicenter Phase 61 UPLYSO 61 efficacy endpoint 61 European Sepsis Trial 61 intranasal formulation 61 generation purine nucleoside 61 ATL/TV# 61 ALKS 61 seliciclib CYC# 61 investigational oral 61 tafamidis 61 ponatinib 61 L BLP# 61 Nasdaq RDEA 61 ORAL Sync 61 PNP inhibitor 61 Phase IIIb study 61 NOX E# 61 VELCADE melphalan 61 masked placebo controlled 61 IPL# 61 Aclidinium 61 ofatumumab HuMax CD# 61 metastatic castration resistant 61 carfilzomib 61 Azedra TM 61 Carfilzomib 61 elagolix 61 Alpharadin 61 antibody MAb 61 VEGF Trap 61 AIR CF2 61 Pyridorin 61 Ereska 61 Phase 2a Clinical Trial 61 PEG Interferon lambda 61 IDX# 61 Serdaxin ® 61 Prosaptide 61 Tasimelteon 61 afatinib 61 APPRAISE 61 Phase 2a proof 61 EchoCRT 61 AEGR 61 Phase III Trial 61 Onrigin 61 Phase III Clinical Trial 61 Milnacipran 61 oral rivaroxaban 61 randomized controlled multicenter 61 ENDEAVOR III 61 Cloretazine 61 nitazoxanide 61 Hsp# inhibitor 61 targeted radiotherapeutic 61 Ceflatonin 60 arzoxifene 60 PANVAC VF 60 TOLAMBA 60 PSMA ADC 60 CIMZIA TM certolizumab pegol 60 initiated Phase 1b 60 pharmacodynamics 60 dexpramipexole 60 TRO# 60 Marqibo 60 HCD# [002] 60 Debio 60 tolevamer 60 refractory CLL 60 eltrombopag 60 otelixizumab 60 PRECISE trial 60 SCH # 60 TAXUS ATLAS 60 ADX# 60 EXPAREL TM 60 IRX 2 60 diarrhea predominant irritable 60 GLYX 60 IMPACT DCM 60 AIR CF1 60 BCX# 60 GSK# [001] 60 Atu# 60 cangrelor 60 SNT-MC#/idebenone 60 Zoraxel 60 EDEMA4 60 RGB # 60 celgosivir 60 GetGoal Phase III 60 AACR NCI EORTC 60 Hsp# Inhibitor 60 Phase IIb Clinical Trial 60 novel histone deacetylase 60 histamine dihydrochloride 60 HGS ETR2 60 XmAb# 60 Genasense ® 60 PEG IFN 60 BLA filing 60 label dose escalation 60 peginesatide 60 omacetaxine 60 dextromethorphan quinidine 60 Aplidin 60 Intervention Effectiveness 60 CLARITY study 60 placebo controlled randomized 60 darusentan 60 tesmilifene 60 RhuDex 60 metastatic hormone refractory 60 Amigal 60 Triapine 60 Zybrestat 60 LibiGel ® 60 ANTEGREN 60 Ozarelix 60 MBP# [001] 60 FTY# fingolimod 60 lurasidone 60 PreCISe 60 Vicriviroc 60 Cloretazine R 60 thorough QT 60 JZP 60 davunetide 60 daclizumab 60 ALN TTR 60 investigational protease inhibitor 60 assessing T DM1 60 DASISION 60 Prestara 60 Phase #/#a trial 60 indibulin 60 6R BH4 60 LY# [003] 60 RSD# 60 Phase IIa proof 60 refractory chronic lymphocytic 60 AVN# [001] 60 triphendiol 60 sitaxsentan 60 CHAMPION PCI 60 Cotara 60 ACTEMRA TM 60 ThGRF 60 MLN# 60 GW# [003] 60 TRANSFORMS 60 RH1 60 Exherin TM 60 CRD5 60 Diamyd ® 60 dose escalation phase 60 cetrorelix 60 Iluvien ® 60 pharmacodynamics PD 60 Sapacitabine 60 inhaled formulation 60 Locteron ® 60 safety tolerability pharmacokinetics 60 Firazyr 60 TH# [003] 60 humanized monoclonal antibody 60 Hedgehog pathway inhibitor 60 multicenter randomized 60 Trofex 60 acyclovir Lauriad R 60 Desmoteplase 60 CIMZIA TM 60 Ostarine 60 subanalysis 60 apricitabine ATC 60 proteasome inhibitor 60 Tesetaxel 60 REOLYSIN ® 60 subcutaneous SC 60 baminercept 60 cancer neuroendocrine tumor 60 Relivar 60 EndoTAG TM -1 60 Vilazodone 60 CLIRS trial 60 Curaxin CBLC# 60 Luveniq 60 Parkinson disease levodopa induced 60 multicenter 60 perifosine 60 BIBW 60 afamelanotide 60 Phase 2b Clinical Trial 60 cariprazine 60 Xanafide 60 CRMD# 60 Dalbavancin 60 Capesaris 60 Pivotal Trial 60 Zemplar Capsules 60 Darusentan 60 Cimzia TM 60 Hedgehog Pathway Inhibitor 60 Meets Primary Endpoint 60 Personalized Immunotherapy 60 recurrent GBM 60 Asentar 60 PROMACTA 60 Zelrix 60 Investigational Device Exemption IDE 60 crizotinib PF # 60 XL# [003] 60 dasatinib Sprycel ® 60 RE SURGE 60 sunitinib malate 60 oxymorphone ER 60 PrevOnco 60 CG# [003] 60 apremilast 60 Denufosol 60 Urocortin 2 60 evaluating REVLIMID 60 CCX# B 60 NYSE Amex PTN 60 pharmacodynamic effects 60 PEGylated interferon beta 1a 60 Dapagliflozin 59 generation PNP inhibitor 59 SNT MC# 59 Nasdaq NYMX 59 milnacipran 59 octreotide implant 59 BR.# 59 MIRCERA 59 nonclinical studies 59 IPX# 59 Nanobody 59 Omapro 59 oral FTY# 59 adipiplon 59 Panzem R NCD 59 Apoptone 59 Tovaxin 59 prospective randomized multicenter 59 sNDA submission 59 OXi# 59 bendamustine 59 CIMZIA ™ 59 HuLuc# 59 Prodarsan ® 59 Vernakalant 59 novel VDA molecule 59 Canvaxin 59 preclinical toxicology 59 neratinib 59 relapsing remitting MS RRMS 59 NASDAQ NYMX 59 PRE SURGE 59 confirmatory clinical 59 Q#IR 59 polymerase inhibitor 59 ancrod 59 Cladribine Tablets 59 Nasdaq PPHM 59 Panzem R 59 OvaRex 59 pharmacodynamic 59 LUMINATE 59 antisense drug 59 volociximab 59 vemurafenib 59 ORENCIA ® 59 Phase III TRIST 59 lymphoma CTCL 59 Initiates Phase II 59 mapatumumab 59 Lodotra TM 59 CALGB # [002] 59 RELOVAIR ™ 59 DB# [003] 59 Tavocept 59 AVERROES 59 liprotamase 59 microplasmin 59 bardoxolone methyl 59 TPI ASM8 59 INCB# [003] 59 CCX# 59 entinostat 59 ThermoDox ® 59 ascending doses 59 XIENCE V Stent System 59 IMC #B 59 Degarelix 59 synthetic retinoid 59 rALLy 59 Phase III registrational 59 Inc. NASDAQ AVNR 59 adecatumumab MT# 59 rasagiline tablets 59 velafermin belinostat 59 catheter occlusion 59 sorafenib Nexavar 59 IPLEX 59 IIb clinical trial 59 Silodosin 59 AAG geldanamycin analog 59 RE LY ® 59 pradefovir 59 AZILECT ® 59 dirucotide MBP# 59 custirsen 59 ALTU 59 LEP ETU 59 TG# [003] 59 CA4P 59 Sunovion 59 dose dose escalation 59 TG# [001] 59 Northera 59 Hedgehog antagonist 59 unique alkylating agent 59 eosinophilic asthma 59 inhibitor RG# 59 mGluR2 positive 59 Inc. Nasdaq VVUS 59 depsipeptide 59 Oxypurinol 59 active comparator 59 STRIDE PD 59 injectable formulation 59 cetuximab Erbitux R 59 amrubicin 59 PLK1 SNALP 59 LymphoStat B belimumab 59 ocular formulation 59 Clavis Pharma 59 DR Cysteamine 59 thymalfasin 59 CA9 SCAN 59 GOUT 59 EMPHASIS HF trial 59 Cinryze ™ 59 NXL# 59 pharmacokinetic profile 59 refractory metastatic colorectal cancer 59 Relovair 59 ACTEMRA 59 Golimumab 59 cilengitide 59 TOCOSOL Paclitaxel 59 MEK inhibitor RDEA# 59 ZFP Therapeutic 59 canakinumab 59 Omigard 59 Augment Injectable 59 NCCTG 59 telbivudine 59 mGluR2 NAM 59 SUTENT ® 59 AVADO 59 BAL# [002] 59 Nasdaq PGNX today 59 TLK# 59 Nasdaq HALO 59 EVEREST II 59 voreloxin 59 omecamtiv mecarbil 59 EXPAREL ™ 59 SinuNase TM 59 LIALDA 59 mTOR inhibitor 59 Angiocept 59 Nasdaq DVAX 59 REMINYL ® 59 HCV protease inhibitor 59 HDAC Inhibitor 59 Cardio Vascu Grow 59 oral methylnaltrexone 59 ospemifene 59 sulodexide 59 mGluR5 NAM 59 dose escalation 59 systemic RNAi therapeutic 59 dutogliptin 59 Cimzia ® certolizumab pegol 59 integrase inhibitor 59 SPIRIT III 59 ASA# 59 receptor tyrosine kinase inhibitor 59 Catena ® 59 Sulonex 59 bosutinib 59 Troxatyl TM 59 maximally tolerated dose 59 miconazole Lauriad ® 59 mRCC 59 aclidinium 59 Cethrin 59 QNEXA 59 topical formulation 59 ORACLE MS 59 painful diabetic neuropathy 59 Phase 2b Trial 59 mitogen activated ERK kinase 59 SILENOR TM 59 Kahalalide F 59 inhaled liposomal ciprofloxacin 59 albinterferon alfa 2b 59 Zenvia TM 59 Pharmacokinetics PK 59 forodesine hydrochloride 59 Telcyta 59 blinded placebo controlled 59 alagebrium 59 Acute Myeloid Leukemia AML 59 Menerba 59 PI3K/Akt pathway inhibitor 59 interferon gamma 1b 59 refractory AML 59 Nuvion 59 iniparib 59 BLA submission 59 Icatibant 59 CoFactor 59 visilizumab 59 lorcaserin Phase 59 Exherin 59 RoACTEMRA 59 galiximab 59 NLX P# 59 initiate Phase 59 ulimorelin 59 Maximum Tolerated Dose MTD 59 STEDESA 59 Tolvaptan 59 Tesmilifene 59 RRMS patients 59 Board DSMB 59 Genz # 59 Synavive 59 Anturol TM 59 BiTE R 59 trastuzumab DM1 59 Rebif ® 59 safinamide 59 MIVI III 59 administered subcutaneously 59 CAMMS# 59 Pralatrexate 59 Nexavar sorafenib 59 TroVax 59 Cimzia ® 59 linaclotide 59 icatibant 59 PREOS R 59 Thiarabine 59 randomized clinical 59 Tezampanel 59 AZX# 59 Tamibarotene 59 IMC A# 59 cetuximab Erbitux ® 59 pan HDAC inhibitor 59 EDEMA3 trial 59 BENLYSTA ® 59 IIa trials 59 PEGylated Fab fragment 59 telomerase inhibitor drug 59 ularitide 59 Proellex TM 59 EVIZON TM 59 MAXY alpha 59 Genasense oblimersen sodium Injection 59 prospectively defined 59 blind randomized placebo 59 Temsirolimus 58 Nasulin 58 Genasense ® oblimersen 58 prospective randomized placebo 58 ACCLAIM II 58 OncoVEX 58 Onconase

Back to home page